|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Frontline therapy** | **Outcome** | | **Second line therapy** | | **Outcome** | | **Third line therapy** | | **Outcome** | |
| Active surveillance (AS)  *N = 38*  *\*1 outcome missing* | Spontaneous regression | *9*  *(24%)* |  | | | | | | | |
|  |  | None | *11* |  | |  | |  | |
| Stable disease | *16*  *(43%)* | Surgery | *2* | No recurrence | *2* |
| Celecoxib | *1* | Regression | *1* |
| Sorafenib | *1* | Regression | *1* |
| Meloxicam | *1* | Regression | *1* |
| Progression | *12*  *(33%)* | AS | *2* | Stable disease | *2* |  | |  | |
| Surgery | *5* | No recurrence | *5* |
| HIFUa | *1* | Progression | *1* |
| Meloxicam | *1* | Stable disease | *1* |
| Vinorelbine | *3* | Stable disease | *1* |
| Regression | *1* |
| Progression | *1* | Sorafenib | *1* | Regression | *1* |
| Surgery  *N = 23*  *\*1 outcome missing* | No recurrence | *16*  *(73%)* |  | |  | |  | |  | |
| Recurrence | *5*  *(23%)* | AS | *4* | Stable disease | *4* |  | |
| Vinorelbine | *1* | Stable disease | *1* |  | |
| Residual disease (R2) | *1*  *(4%)* | AS | *1* | Stable disease | *1* |  | |
| Celecoxib  *N = 1* | Stable disease | *1* |  | |  | |  | |  | |

Figure 1 – Treatment and treatment outcomes

a) HIFU: High Intensity Focused Ultrasound.